Tirzepatide Beats Semaglutide With 21.6% Weight Loss
The SURMOUNT-5 trial found tirzepatide cut body weight by 21.6% on average versus 15.4% for semaglutide over 72 weeks in adults with obesity but no diabetes.
Tag
eli-lilly
Eli Lilly, Google, Caterpillar Stocks Jump on Earnings
Eli Lilly, Caterpillar, and Google all saw their stocks jump after posting strong quarterly earnings. Eli Lilly's results were driven by rising demand for its weight-loss drugs. The beats point to resilience across pharma, industrials, and digital advertising.
← Back
Tag
eli-lilly
SURMOUNT-5 Trial: Tirzepatide vs Semaglutide in Obesity Management
The SURMOUNT-5 trial found tirzepatide cut body weight by 21.6% on average versus 15.4% for semaglutide over 72 weeks in adults with obesity but no diabetes.
1mo ago · 3 min · Big Stories
Earnings live updates: Eli Lilly stock jumps as weight-loss drugs boost results, Caterpillar rises, Google surges
Eli Lilly, Caterpillar, and Google all saw their stocks jump after posting strong quarterly earnings. Eli Lilly's results were driven by rising demand for its weight-loss drugs. The beats point to resilience across pharma, industrials, and digital advertising.
2mo ago · 1 min · Markets
— End of feed —